Makers of medical devices that use artificial intelligence are clamoring for clarity from the Food and Drug Administration about its approval framework for devices evolving in real time.

Manufacturers applauded the FDA in April when it issued draft guidance known, in short, as the Predetermined Change Control Plan for AI. A PCCP would allow device makers in the initial premarket submission of a product to essentially prespecify future capabilities of a device without resubmitting it later for approval.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]